🔥 TODAY COULD BE ONE OF THE DEFINING MOMENTS OF #ESMO26! 🔥
The ESMO Presidential Symposium is always one of the highlights of the congress, and today’s session promises some truly extraordinary science!
If I had to pick ONE study with the greatest potential to change clinical practice at ESMO 2026, my choice would be DeLLphi-305.
For decades, SCLC has been one of the most challenging diseases in oncology, with far too little progress and far too few therapeutic breakthroughs.
Could DeLLphi-305 finally represent the major leap forward we have been waiting for? We already know that adding tarlatamab to durvalumab as first-line maintenance significantly improves OS compared with durvalumab alone. But today, we will finally see the numbers. And I am genuinely excited to discover just how transformative this benefit might be! My personal bet for the biggest breakthrough of #ESMO26? DeLLphi-305. @StephenVLiu @sands_jacob
Of course, the magnitude of survival benefit, safety and clinical applicability will ultimately determine its impact. But the potential is enormous. Don’t miss today’s Presidential Symposium!
Madrid | 🕟 16:30 CEST Alicante auditorium
#ESMO26 #ESMOAmbassador #SCLC #LungCancer #Immunotherapy #Oncology #PracticeChanging